IgA nephropathy (IgAN) involves the abnormal deposition of IgA antibodies in the kidneys, leading to chronic inflammation and progressive renal damage. It is the most common primary glomerulonephritis globally, with variable clinical outcomes and a significant impact on renal function in some patients. IgAN typically manifests in young to middle-aged adults, with a slight male predominance in some populations. There are notable geographical differences in prevalence, with higher rates observed in Asian countries compared to Western countries.
The diagnosis of IgAN must be confirmed by kidney biopsy showing mesangial IgA deposits with or without other histological changes. Treatment strategies focus on controlling blood pressure, reducing proteinuria, and managing progression with medications like ACE inhibitors or ARBs. Immunosuppressive therapy may be considered in certain cases with progressive disease. Novel strategies for management include the DEARA approach: Dual Endothelin and Angiotensin II Receptor Antagonists, which offer a targeted therapy to reduce proteinuria.
In this series of programs, our expert faculty will review the epidemiology, pathophysiology, genetics, and supportive treatment form IgAN, including new specific therapies. We will also discuss team management—from PCP to nephrologist—and supportive patient education to achieve continuity of care and adherence to optimal treatment strategies in IgAN.
Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers involved in the care of patients with VTE
Develop effective strategies for patient education and shared decision making to achieve continuity of care and adherence to optimal treatment of patients with IgAN
Team Management—from PCP to Nephrologist—and Supportive Patient Education to Achieve Continuity of Care and Adherence to Optimal Treatment Strategies in IgAN
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Edgar Lerma, MD | Consultant/Advisor: Vifor; Otsuka; Bayer
Speaker’s Bureau: AstraZeneca; Bayer; Otsuka |
Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours.
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-24-017-H01-P).
Learners should only claim credit commensurate with the extent of their participation.
This activity has been supported by an independent educational grant from Travere Therapeutics.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and from Travere Therapeutics do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
CME and CNE credit will be issued appropriate certificate of completion.
Others may request a “certificate of completion”.
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.
For all CE inquiries or special needs, please contact admin@academiccme.com.
